GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » EV-to-Revenue

Eupraxia Pharmaceuticals (TSX:EPRX) EV-to-Revenue : (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Eupraxia Pharmaceuticals's enterprise value is C$94.11 Mil. Eupraxia Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00 Mil. Therefore, Eupraxia Pharmaceuticals's EV-to-Revenue for today is .

The historical rank and industry rank for Eupraxia Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

TSX:EPRX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.83
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), Eupraxia Pharmaceuticals's stock price is C$3.65. Eupraxia Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00. Therefore, Eupraxia Pharmaceuticals's PS Ratio for today is .


Eupraxia Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Eupraxia Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals EV-to-Revenue Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - - - - -

Eupraxia Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eupraxia Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eupraxia Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's EV-to-Revenue falls into.



Eupraxia Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Eupraxia Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=94.108/0
=

Eupraxia Pharmaceuticals's current Enterprise Value is C$94.11 Mil.
Eupraxia Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eupraxia Pharmaceuticals  (TSX:EPRX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Eupraxia Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3.65/0
=

Eupraxia Pharmaceuticals's share price for today is C$3.65.
Eupraxia Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eupraxia Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Traded in Other Exchanges
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.
Executives
James Allen Helliwell Director